fda compounding semaglutide enforcement news november 2025 FDA's GLP-1 decision kicks off 'unprecedented' tussle over shortage Compounded weight loss injections —

Eat Smart with Whole Foods Your plate is a powerful tool

For obesity management, NICE has issued relevant guidance and technology appraisals that define NHS eligibility criteria which are distinct from marketing authorisation alone: NICE TA875 covers semaglutide (Wegovy) for managing overweight and obesity, with specific BMI and comorbidity eligibility criteria and requirements for specialist service involvement

Importantly, the trial also included lifestyle counseling on diet and physical activity, but the significant weight loss observed in the Retatrutide groups clearly indicated that the drug itself played a major role

In an emergency for example, if you experience difficulty breathing, facial or throat swelling, severe chest pain, or severe abdominal pain (which may indicate a serious reaction such as anaphylaxis or pancreatitis) call 999 immediately